Protocol for treatment under Hospital Exemption:T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting transforming growth factor beta receptor type II (TGFβII)

Cancer type: Colorectal cancer

Phase: I/II

Principal Investigator: Dueland Svein

Country: NO

Keywords: Norway, Oslo, T cell receptor, colorectal, MSI, TGFβII

Status: Inclusion completed

Link to